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Abstract Two protein kinases that are involved in proliferation 
and oncogenesis but so far were thought to be functionally 
independent are Raf and CK2. The Raf signaling pathway is 
known to play a critical role in such fundamental biological 
processes as cellular proliferation and differentiation. Abnormal 
activation of this pathway is potentially oncogenic. Protein 
kinase CK2 exhibits enhanced levels in solid human tumors and 
proliferating tissue. In a two-hybrid screen of a mouse-embryo 
cDNA library we detected an interaction between A-Raf and 
CK2ß subunit. This binding was specific, as no interaction 
between CK2ß and B-Raf or c-Raf-1 was observed. Regions 
critical for this interaction were localized between residues 550 
and 569 in the A-Raf kinase domain. A-Raf kinase activity was 
enhanced 10-fold upon coexpression with CK2ß in Sf9 cells. The 
a subunit of CK2 abolishes this effect. This is the first 
demonstration of both a direct Raf-isoform-specific activation 
and a regulatory role for CK2ß independent of the CK2a 
subunit. The present data thus link two different protein kinases 
that were thought to work separately in the cell. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The family of cytoplasmic Raf serine/threonine kinases 
comprises three members in mammals: c-Raf-1, B-Raf and 
A-Raf. They have a high degree of similarity, consisting of 
three conserved regions, CRI, CR2 and CR3. The CRI region 
includes the Ras binding domain that is responsible for re-
cruitment of Raf kinases to the cellular membrane and sub-
sequent activation during growth factor stimulation. The CR3 
region represents the catalytic domain. Deletion of the regu-
latory N-terminal half of all three Raf kinases leads to con-
stitutively active oncogenic forms. Whereas an essential role 
of the ubiquitously expressed c-Raf-1 in the control of cellular 
proliferation and transformation is well established, little is 
known about potential specific functions of A-Raf and B-
Raf [1]. Besides the preferential mRNA expression of A-Raf 
in urogenital tissues [2], a differential regulation of A-Raf in 
comparison to c-Raf-1 was shown during NGF-induced dif-
ferentiation of pheochromocytoma PC 12 cells [3] and in ven-
tricular myocytes' response to growth-promoting stimuli [4]. 
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Little is known about a Raf-isozyme-specific regulation. 
Therefore, a mouse-embryonic cDNA library was screened 
using the two-hybrid system with A-Raf as a bait leading to 
the isolation of CK2ß. 
CK2ß is the regulatory subunit of protein kinase CK2, a 
ubiquitously expressed serine/threonine protein kinase [5-7]. 
The CK2 holoenzyme is a heterotetrameric complex (0^2)-
Two ß subunits dimerize and bind two catalytic a subunits to 
form the holoenzyme [8,9]. 
Although there are several reports on a potential role of 
CK2 in cell proliferation and tumorigenesis [10-12], not 
very much is known about its regulation and physiological 
function. There is some evidence that the subunits may also 
have a function when they occur separated from each other 
[13-15]. Overexpression of CK2ß in Schizosaccharomyces 
pombe, an organism that does not contain a Raf homolog, 
leads to inhibition of cell growth and cytokinesis, resulting in 
a multiseptated phenotype [16], whereas CK2oc overexpression 
has no effect. 
In multicellular organisms that carry a full complement of 
Raf enzymes, the effect of ß overexpression on cellular phe-
notype has not yet been evaluated. Here we report that A-Raf 
specifically binds the regulatory ß-subunit of protein kinase 
CK2 and this leads to activation of A-Raf kinase, independ-
ent of CK2a. 
2. Materials and methods 
2.1. Screening a two-hybrid library with A-Raf as a bait and direct 
interaction tests 
A 14.5 day mouse-embryo cDNA library with 1.92X 106 independ-
ent inserts cloned in pPC67 as fusion with the Gal4 activation domain 
[17] was cotransformed with A-Raf cloned in pPC97 as a fusion with 
the Gal4 DNA-binding domain into the yeast strain HF7c [18]. Pos-
itive clones were monitored by growth on medium lacking histidine 
and activity of the lacZ-reporter gene in filter assays. Replica filters of 
transformants were frozen in liquid nitrogen and incubated in Z buffer 
(16.1 g/1 Na2HP04-7H20, 5.5 g/1 NaH2P04-H20, 0.75 g/1 KC1, 0.246 
g/1 MgS04-7H20) which contained 0.27 ml 2-mercaptoethanol and 
1.67 ml X-gal (20 mg/ml in dimethylformamide) per 100 ml at 30°C 
for up to 12 h. 
Of 9.9 xlO6 transformants screened, 57 clones were His and lacZ 
positive and further analysed by sequencing and colony hybridization. 
For direct interaction tests yeast strain HF7c was cotransformed 
with Raf deletion constructs cloned in pPC97 and the CK2ß full 
length clone isolated from the mouse library. Transformants were 
then handled as described above. 
2.2. Expression in insect cells 
Sf9 cells were grown in IPL-41 Insect Medium under standard 
culture conditions. 107 Sf9 cells were infected with baculoviruses (10 
MOI/cell) expressing CK2a, CK2ß and A-, B- or c-Raf-1 genes. After 
48 h cells were washed twice with PBS and lysed in Triton buffer (50 
mM Tris-HCl pH 8.0, 137 mM NaCl, 1% Triton X-100, 10 mM Na-
pyrophosphate, 25 mM Na-glycerophosphate, 2 mM EDTA, 2 mM 
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Fig. 1. Interaction of Raf isozymes with CK2ß and mapping of the 
binding sites. Two hybrid tests of different Raf constructs with 
CK2ß. In addition to the constructs shown, the A-Raf deletion con-
structs A-Raf(l-491), A-Raf(1^128), A-Raf(l-310), and A-Raf(255-
530) were tested with negative results. CR, conserved regions; His+, 
growth on medium lacking histidine; lacZ+, activity of the lacZ re-
porter gene. 
EGTA, 10% glycerol, 0.1% 2-mercaptoethanol, 1 mM Na-vanadate, 
25 mM NaF, 0.01% leupeptin, 0.01% aprotinin, 2 mM pepstatin). The 
lysates were cleared by centrifugation at 10000 rpm for 5 min. 
2.3. Immunoprecipitation 
900 ug of total cell lysates were used for immunoprecipitation of 
Raf proteins. The anti-Raf antibodies were raised against synthetic 
peptides representing the 12 C-terminal residues of A- and c-Raf-1 
and the 13 C-terminal residues of B-Raf, respectively. After incuba-
tion at 4°C for 2 h immunoprecipitates were washed twice with Triton 
buffer and once with HEPES buffer (25 mM HEPES pH 7.5, 25 mM 
Na-glycerophosphate, 1.5 mM EGTA, 5% glycerol, 1 mM DTT) and 
divided into aliquots for (i) immunocomplex kinase assays (see below) 
and (ii) immunodetection of Raf. After resolving samples by SDS-
PAGE and electroblotting onto nitrocellulose membrane, immunode-
tections were performed with Raf-specific antisera using the ECL 
detection system (Amersham). 
2.4. Immunocomplex kinase assay 
Aliquots of Raf immunocomplexes were resuspended in 30 (il of 
kinase buffer (25 mM HEPES pH 7.5, 25 mM Na-glycerophosphate, 
1.5 mM EGTA, 5% glycerol, 1 mM DTT, 10 mM MgCl2, 100 |xM 
ATP, 5 uCi [y-32P]ATP (3000 Ci/mM, Amersham) containing 50 ug/ 
ml of recombinant K97M kinase dead MEK mutant protein and 
incubated at 30°C for 15 min. After resolving by SDS-PAGE, samples 
were electroblotted onto nitrocellulose. Quantification of kinase activ-
ity and the amount of Raf proteins (using 35S-labelled secondary anti-
bodies) was done using the Bio Imaging Analyzer BAS 2000 (Fuji). 
3. Results and discussion 
3.1. A-Raf interacts specifically with CK2$ 
In a two-hybrid screen [19] of a mouse embryonic cDNA 
library with A-Raf as bait 57 positive clones were detected. 
Sequencing and colony hybridization revealed that one clone 
represents H-Ras and 56 were identified as CK2ß. Eight of 
these 56 clones were sequenced, representing two independent 
clones, one full-length clone and one lacking the 17 N-termi-
nal amino acids. In a parallel screen of the same library with 
B-Raf as bait no CK2ß was found (Hagemann et al., unpub-
lished results). 
This was the first indication that CK2ß may interact specif-
ically with A-Raf. To test this hypothesis and in order to map 
interaction sites we performed direct two-hybrid tests using all 
three Raf isoforms and different A-Raf deletion constructs 
(Fig. 1). These tests showed that CK2ß interacts exclusively 
with A-Raf but not with c-Raf-1 or B-Raf. From large N- or 
C-terminal deletion mutants of A-Raf only A-Raf(255-606) 
showed an interaction with full length CK2ß. Further dele-
tions of A-Raf(255-606) from the C-terminal end still showed 
an interaction when amino acids 255-569 were present, but 
not when the C-terminus was further deleted until amino acid 
549. This means that residues 255-569 of A-Raf are sufficient, 
Fig. 2. CK2ß subunit activates A-Raf (A), but not B-Raf (B) or c-Raf-1 (C). The amount of precipitated Raf protein was compared within in-
dividual panels (A, B, or C) using 35S-labelled secondary antibodies and the variation was £25%. Values of Raf kinase activity from triplicate 
experiments were normalized to the activity of Raf alone, which was arbitrarily chosen as 1. 
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and residues 550-569 are necessary for binding of CK2ß. The 
present data, however, do not indicate whether residues 550-
569 are directly involved in binding, or whether they are nec-
essary for maintaining the correct 3-dimensional structure of 
the binding site. Amino acids 550 to 569 correspond to the C-
terminal half of subdomain XI of the A-Raf kinase domain 
[20]. This region includes residues which are highly conserved 
between the different Raf proteins as well as A-Raf-isozyme-
specific sequences, which may account for the A-Raf-specific 
binding. We were not able to find a direct interaction of A-
Raf with the a subunit of CK2 (not shown), whereas a tri-
meric complex between CK2a, CK2ß and A-Raf was not 
excluded. 
3.2. CK2\i activates A-Raf in immunocomplex kinase assays 
In order to address the physiological significance of these 
observations we asked whether the association with the CK2 
subunits would influence the kinase activity of A-Raf. We 
expressed the individual Raf isozymes together with CK2ß, 
CK2a, or both, in insect cells. Raf was immunoprecipitated 
using Raf-isozyme-specific antisera and the Raf immunocom-
plexes were subjected to kinase assays with bacterially ex-
pressed MEK as substrate (Fig. 2). Neither the two CK2 
subunits alone nor together were able to phosphorylate 
MEK above basal level. In the case of A-Raf, MEK phos-
phorylation was significantly enhanced (10-fold) after coex-
pression of CK2ß, but not of CK2oc. Coexpression of 
CK2oc, CK2ß and A-Raf in a triple infection reduced the A-
Raf activity back to basal level. In contrast, MEK phosphor-
ylation by B-Raf and c-Raf-1 was not affected by both CK2ß 
or CK2oc, alone or in combination. 
The present data clearly demonstrate that the regulatory ß 
subunit of CK2 alone can act as a specific activator of A-Raf. 
The a subunit abolishes this activation, most probably by 
competing with A-Raf for binding to CK2ß. As CK2ß in 
vivo exists as a dimer that interacts with two CK2a mono-
mers to form the active, heterotetrameric CK2 enzyme [21], it 
might be possible that heterotetramenzation with two A-Raf 
molecules is responsible for CK2ß-mediated A-Raf activation. 
Activation by protein-protein interaction in the kinase domain 
is not restricted to A-Raf, as we have observed that the kinase 
activity of c-Raf-1 was enhanced in vivo and in vitro by bind-
ing to the Bcl-2 family protein BAG-1 [22]. 
Our data suggest a new mode of isozyme-specific Raf kin-
ase regulation, which depends on the availability of free 
CK2ß. There is some evidence that isolated Ck2 subunits 
are present in cells [13], as rapidly proliferating tissue culture 
cells and human kidney tumors synthesize the ß subunit in 
excess of the a subunit [14,15]. Since A-Raf shows highest 
expression levels in urogenital tissue [2], CK2ß mediated A-
Raf activation might be involved in the formation of these 
tumors. 
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